HAP Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History

HAP Trading’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-10,300	Closed	-$10K	–	2543
2021 Q3	$10K	Buy	+10,300	New	+$813K	﹤0.01%	2005
2021 Q1	–	Sell	-11,700	Closed	-$33K	–	1946
2020 Q4	$33K	Buy	+11,700	New	+$928K	﹤0.01%	1546
2019 Q3	–	Sell	-31,300	Closed	-$8K	–	1231
2019 Q2	$8K	Buy	+31,300	New	+$2.68M	﹤0.01%	983
2019 Q1	–	Sell	-30,000	Closed	-$1K	–	1111
2018 Q4	$1K	Buy	+30,000	New	+$2.85M	﹤0.01%	1084
2016 Q4	–	Sell	-121,200	Closed	-$42K	–	994
2016 Q3	$42K	Buy	+121,200	New	+$11.4M	﹤0.01%	727
2016 Q1	–	Sell	-103,800	Closed	-$39K	–	804
2015 Q4	$39K	Buy	+103,800	New	+$10.8M	﹤0.01%	669

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HAP Trading's BMRN Position: Q2 2025 in Review

HAP Trading sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 11,634 shares — an estimated $822K sold.

HAP Trading first reported a position in BMRN in Q4 2016 and held it in 15 quarters. The position peaked at $7.56M in Q2 2018. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

HAP Trading reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
HAP Trading sold 11,634 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $822K.
HAP Trading first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 15 quarters.
HAP Trading's BioMarin Pharmaceuticals position peaked at $7.56M in Q2 2018.
582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on HAP Trading's 13F filing for Q2 2025, filed 13 Aug 2025.